Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque Psoriasis

 Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque Psoriasis

Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque Psoriasis

Shots:

  • The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1,800 patients with moderate-to-severe plaque psoriasis across 200 sites WW
  • reSURFACE 1 & reSURFACE 2 studies result: @12wks. PASI 75 (75%); @28wks. PASI 90 (54%), PASI 100 (29%); well tolerated; low AEs & discontinuation rates
  • Ilumetri (tildrakizumab, SC, 100mg, q3mt) is a mAb targeting interleukin IL 23 p19 with its expected NICE approval in Apr’19. It has also received EU approval in Sept’18, codeveloped & co commercialize by Almirall & Sun Pharma under an agreement July’16

Click here to read full press release/ article | Ref: Almirall | Image: Okdiario

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post